Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study
Acta Ophthalmologica · 2025
DOI: 10.1111/aos.17475 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Imadeddin Abu Ishkheidem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Gothenburg University, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Dexamethasone, Ocular Hypertension, Macular Edema, Intraocular Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Gothenburg Society of Medicine.
Abstract (Originalsprache)
Purpose
To evaluate the incidence and risk factors for secondary ocular hypertension (SOHT) following intravitreal dexamethasone implants (Ozurdex®) in patients with diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (RVO) in a Swedish cohort.
Methods
This retrospective study included 309 eyes from 249 patients treated with Ozurdex® at Sahlgrenska University Hospital, Mölndal, Sweden, from 1 January 2016 to 31 December 2023. Electronic medical records were reviewed for data including patient demographics, number of injections, incidence of and treatment modalities for SOHT and rate of Ozurdex® discontinuation.
Results
Of the 309 eyes, 217 (70.2%) were in the DME group and 92 (29.8%) in the RVO group. Overall, 117 eyes (37.9%) developed SOHT (intraocular pressure (IOP) ≥25 mmHg or a rise of ≥10 mmHg from baseline); this included 77 of 217 DME eyes (35.5%) and 40 of 92 RVO eyes (43.5%). Men were more than twice as likely as women to develop SOHT (adjusted odds ratio [aOR]: 2.53, p < 0.001). Each unit increase in baseline IOP was associated with an 8% increase in the odds of SOHT (aOR: 1.08 p = 0.025). Of all eyes, 30.5% received IOP‐lowering treatment, primarily prostaglandins. None required invasive surgery.
Conclusion
Our finding that 30.5% of eyes received IOP‐lowering treatment confirms that SOHT is a prevalent complication following intravitreal dexamethasone implants. Male gender and higher baseline IOP were key indicators for developing SOHT after Ozurdex® treatment, emphasizing the need for vigilant monitoring. Most cases were managed with IOP‐lowering eye drops, indicating that while common, SOHT is typically manageable without invasive interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Gothenburg University, Gothenburg, Sweden.
- Department of Ophthalmology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- The Swedish Digital Ophthalmology Centre, Linkoping, Sweden.
- Department of Ophthalmology, Faculty of Medicine and Health, Örebro University, Orebro, Sweden.
ORCID-Profile: Imadeddin Abu Ishkheidem, Madeleine Zetterberg, Abbas Al-Hawasi, Marita Andersson Grönlund
Förderung
- The Gothenburg Society of Medicine
Zitieren
APA
Abu Ishkheidem, I., Breimer, M., Kamal, S., Zetterberg, M., Al-Hawasi, A., & Grönlund, M. A. (2025). Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study. Acta Ophthalmologica. https://doi.org/10.1111/aos.17475
Vancouver
Abu Ishkheidem I, Breimer M, Kamal S, Zetterberg M, Al-Hawasi A, Grönlund MA. Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study. Acta Ophthalmologica. 2025. doi:10.1111/aos.17475
BibTeX
@article{AbuIshkheidem2025,
author = {Abu Ishkheidem, Imadeddin and Breimer, Martin and Kamal, Saba and Zetterberg, Madeleine and Al-Hawasi, Abbas and Grönlund, Marita Andersson},
title = {Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study},
journal = {Acta Ophthalmologica},
year = {2025},
doi = {10.1111/aos.17475}
}
EUVIMED